The IMpower150 study evaluated atezolizumab combined with bevacizumab and chemotherapy in the first-line treatment of non-squamous NSCLC patients, including EGFR and ALK mutant populations, and the results confirm that patients in ABCP group have significant survival benefits[86]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.